Darifenacin: a muscarinic M₃-selective receptor antagonist for the treatment of overactive bladder

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 61:37-49.
   PubMed Web of Science ®Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 87:760-766.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20:327-336.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH, BENTKOVER JD et al.: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61:1123-1128.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, KELLEHER CJ, KERR LA, ROGERS RG: Overactive bladder significantly affects quality of life. Am. J. Manag. Care (2000) 6(11 Suppl.):S580-S590.
   PubMed Web of Science ®Google Scholar
• TUBARO A: Defining overactive bladder: epidemiology and burden of disease. Urology (2004) 64:2-6.
   PubMed Web of Science ®Google Scholar
• FETSCHER C, FLEICHMAN M, SCHMIDT M, KREGE S, MICHEL MC: M3 Muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. (2002) 136:641-643.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K-E: Potential benefits of muscarinic M3 receptor selectivity. Eur. Urol. Suppl. (2002) 1:23-28.
   Web of Science ®Google Scholar
• BEAUMONT KC, CUSSANS NJ, NICHOLS DJ, SMITH DA: Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog, and man. Xenobiotica (1998) 28:63-75.
   PubMed Web of Science ®Google Scholar
• IKEDA K, KOBAYASHI S, SUZUKI M et al.: M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharm.acol (2002) 366:97-103.
   PubMed Web of Science ®Google Scholar
• NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Presented at the International Continence Society Annual Meeting. Heidelberg, Germany (2002) Abstr. 445.
   Google Scholar
• NAPIER C, LASKEY P, GUPTA P, CLARKE NP: Competitive and reversible interaction of darifenacin with human recombinant M3 receptors. Eur. Urol. Suppl. (2003) 2:A780 (abstract).
   Google Scholar
• SMITH CM, WALLIS RM: Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J. Recept. Signal Transduct. Res. (1997) 17:177-184.
   PubMed Web of Science ®Google Scholar
• NELSON CP, GUPTA P, NAPIER CM, NAHORSKI SP, CHALLISS RAJ: Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea-pig urinary bladder and submandibular salivary gland. J. Pharmacol. Exp. Ther. (2004) 310:1255-1265.
   PubMed Web of Science ®Google Scholar
• NEWGREEN DT, NAYLOR AM: Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutynin. Br. J. Pharmacol. (1996) 117(Suppl.):107P (Abstr.).
   Web of Science ®Google Scholar
• MIYAMAE K, YOSHIDA M, MURAKAMI S et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology (2003) 69:205-211.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M: Comparison of pharmacological effects on various antimuscarinic drugs on human isolated urinary bladder. Neurourol. Urodyn. (2001) 20:462-463 (Abstr. 57).
   Google Scholar
• CHAPPLE CR, ABRAMS P: Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur. Urol. (2005) 48:102-109.
   PubMed Web of Science ®Google Scholar
• ZINNER N, TUTTLE J, MARKS L: Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol. (2005) 23:248-252.
   PubMed Web of Science ®Google Scholar
• SKERJANEC A: The clinical pharmacokinetics of darifenacin. Clin. Pharmacokinet. (2006) 45:325-350.
   PubMed Web of Science ®Google Scholar
• KERBUSCH T, WÄHLBY U, MILLIGAN PA, KARLSSON MO: Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. (2003) 56:639-652.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, STEERS W, NORTON P et al.: A pooled analysis of three Phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. (2005) 95:993-1001.
   PubMed Web of Science ®Google Scholar
• FOOTE J, GLAVIND K, KRALIDIS G, WYNDAELE JJ: Treatment of overactive bladder in the older patient: pooled analysis of three Phase III studies of darifenacin, an M3 selective receptor antagonist. Eur. Urol. (2005) 48:471-477.
   PubMed Web of Science ®Google Scholar
• STEERS W, CORCOS J, FOOTE J, KRALIDIS G: An investigation of dose titration with darifenacin, an M3 selective receptor antagonist. BJU Int. (2005) 95:580-586; Erratum: BJU Int. (2005) 95:1385-1386.
   PubMed Web of Science ®Google Scholar
• HAAB F, CORCOS J, SIAMI P et al.: Long-term darifenacin treatment for overactive bladder: results of a 2-year, open-label extension study. BJU Int. (2006) 98(5):1025-1032.
   PubMed Web of Science ®Google Scholar
• HAAB F, HILL S, LHERITIER K, KAWAKAMI FT, GITTELMAN M: Long-term treatment of overactive bladder with darifenacin in older patients: analysis of responder rates in a 2-year, open-label extension study. Eur. Urol. Suppl. (2006) 5:117.
   Google Scholar
• THOMAS S, ROMANZI L, LHERITIER K: Constipation and associated intervention in patients with overactive bladder treated with darifenacin or tolterodine. Int. Urogynecol. J. (2005) 16(Suppl. 2):101 (Abstr. 306).
   Google Scholar
• HAAB F, STEWART L, DWYER P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. (2004) 45:420-429.
   PubMed Web of Science ®Google Scholar
• HILL S, KHULLAR V, WYNDAELE, LHERITIER K, DARIFENACIN STUDY GROUP: Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2006) 17:239-247.
   PubMed Web of Science ®Google Scholar
• KAY G, WESNES K: Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int (2005) 96:1055-1062.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, KOLODNER K, WESNES K: Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol. (2005) 173:493-498.
   PubMed Web of Science ®Google Scholar
• KAY G, CROOK T, REKEDA L et al.: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. (2006) 50:317-326.
   PubMed Web of Science ®Google Scholar
• CROOK TH, LEBOWITZ D, PIROZZOLO FJ et al.: Recalling names after introduction: changes across the adult life span in two cultures. Development Neuropsychol. (1993) 9:103-113.
   Web of Science ®Google Scholar
• SERRA DB, AFFRIME MB, BEDIGIAN MP, GREIG G, MILOSAVLJEV S, SKERJANEC A, WANG Y: QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J. Clin. Pharmacol. (2005) 45:1038-1047.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. (1997) 104:1374-1379.
   PubMedGoogle Scholar
• REESE PR, PLEIL AM, OKANO GJ, KELLEHER CJ: Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Qual. Life Res. (2003) 12:427-442.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, KELLEHER C, PERRAULT L: Darifenacin, an M3 selective receptor antagonist, improves quality of life in patients with overactive bladder. Progrés en Urologie (2004) 14(Suppl. 3):22 (Abstr. 67).
   PubMedGoogle Scholar
• YOUNG J, LHERITIER K, STEEL M, DWYER P: QoL outcomes during long-term treatment with darifenacin for overactive bladder (OAB): a 2-year, open-label extension study. Qual. Life Res. (2005) 14(9):2036 (Abstr. P-36/1678).
   Google Scholar
• ZINNER N, SUSSET J, GITTELMAN M, ARGUINZONIZ M, REKEDA L, HAAB F: Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OAB. Int. J. Clin. Pract. (2006) 60:119-126; Erratum: Int. J. Clin. Pract. (2006) 60:890.
   Google Scholar
• COYNE KS, MATZA LS, THOMPSON CL: The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual. Life Res. (2005) 14(3):849-855.
   PubMed Web of Science ®Google Scholar